Hepatic Cirrhosis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Zydus, Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Akero

According to DelveInsight's’ estimates, the hepatic cirrhosis market in 7MM is expected to show positive growth during the forecast period (2023–2032), mainly attributed to new product launches, a robust pipeline of emerging therapies, and government support for clinical development.

New York, USA, April 27, 2023 (GLOBE NEWSWIRE) -- *Hepatic Cirrhosis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Zydus, Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Akero*

*According to DelveInsight's’ estimates, the hepatic cirrhosis market in 7MM is expected to show positive growth during the forecast period (2023–2032), mainly attributed to new product launches, a robust pipeline of emerging therapies, and government support for clinical development. *

DelveInsight’s *Hepatic Cirrhosis Market Insights* report includes a comprehensive understanding of current treatment practices, hepatic cirrhosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

*Key Takeaways from the Hepatic Cirrhosis Market Report*

· As per DelveInsight analysis, the hepatic cirrhosis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
· Through DelveInsight’s analysis, it can be observed that hepatic cirrhosis cases show an increasing trend in the forecasted period in the United States. 
· Leading hepatic cirrhosis companies such as *Madrigal Pharmaceuticals, Inc., Zydus Therapeutics Inc., PharmaIN, Rebiotix Inc., Grifols Therapeutics LLC, Exelixis, Vir Biotechnology, Inc., Lipocine Inc, Vedanta Biosciences, Inc., NGM Biopharmaceuticals, Inc, BioVie Inc., Ocelot Bio, Inc, Genfit, CymaBay Therapeutics, Inc., Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Akero Therapeutics, Inc, HighTide Biopharma Pty Ltd, Intercept Pharmaceuticals, Kowa Research Institute, Inc., COUR Pharmaceutical Development Company, Inc., *and others are developing novel hepatic cirrhosis drugs that can be available in the hepatic cirrhosis market in the coming years.
· Some of the key therapies for hepatic cirrhosis treatment include *Resmetirom, Saroglitazar Magnesium, PHIN-214 Subcutaneous injection, RBX7455, Albutein 20% Injectable Solution, Cabozantinib, VIR-2218, VIR-3434, LPCN 1148, VE303, Aldafermin, BIV201 continuous infusion, OCE-205, Elafibranor, Seladelpar, Namodenoson, BMS-986263, BI 685509, EFX, HTD1801, Bezafibrate, K-877-ER, CNP-104, MGL-3196**, *and others.
· Several hepatic cirrhosis therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major hepatic cirrhosis market share @ *Hepatic Cirrhosis Market Report*

*Hepatic Cirrhosis Overview*

Hepatic Cirrhosis is a late-stage liver condition in which good liver tissue is replaced with scar tissue, causing permanent damage to the liver. Many liver disorders and conditions cause cell death and inflammation in healthy liver cells. This is followed by cell repair and, as a result of the repair process, tissue scarring. Scar tissue obstructs blood flow through the liver, slowing its capacity to metabolize nutrients, hormones, medicines, and natural poisons. It also lowers the liver's production of proteins and other chemicals. Cirrhosis eventually prevents the liver from functioning normally. Cirrhosis in its advanced stages is lethal.

Cirrhosis is most commonly caused by hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH) in the industrialized world, whereas hepatitis B virus (HBV) and HCV are the most common causes in the poor world. Cirrhosis can also be caused by other conditions such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure. As the liver’s function progressively declines, liver cirrhosis frequently goes untreated and unreported. As a result, it is critical to have regular exams. Abdominal ultrasonography, elastography, body magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP), biopsies, and other imaging tests are used for hepatic cirrhosis diagnosis.

*Hepatic Cirrhosis Epidemiology Segmentation*

The hepatic cirrhosis epidemiology section provides insights into the historical and current hepatic cirrhosis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The *hepatic cirrhosis market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

· Total Hepatic Cirrhosis Prevalent Cases
· Hepatic Cirrhosis Gender-specific Cases
· Hepatic Cirrhosis Age-specific Cases 
· Hepatic Cirrhosis Etiology-specific Cases

Download the report to understand which factors are driving hepatic cirrhosis epidemiology trends @ *Hepatic Cirrhosis Epidemiological Insights*

*Hepatic Cirrhosis Treatment Market *

Cirrhosis treatment techniques may differ depending on the disease stage and underlying etiology. In general, the treatment goals for compensated cirrhosis are to slow, stop, or reverse fibrosis progression and prevent decompensation events. In contrast, treatment goals for decompensated cirrhosis are to prevent further decompensation and death (e.g., by improving liver function) and to treat complications related to portal hypertension. *EPCLUSA (Gilead Sciences) *has been licensed by the US Food and Drug Administration to treat adult patients with chronic hepatitis C virus (HCV), both with and without cirrhosis. EPCLUSA is licensed for use in patients with moderate to severe cirrhosis in combination with the medication *ribavirin*.

Hepatic cirrhosis patients are also given statins and vaptans. *Tolvaptan *is recommended for hepatic cirrhosis treatment when renal function is preserved. *Statins *used in cirrhosis include atorvastatin, fluvastatin, lovastatin, pitavastatin, and simvastatin. Because of their pleiotropic qualities, statins are beneficial in the treatment of dyslipidemia in patients with liver disease. These qualities, such as alleviating endothelial dysfunction or possessing antioxidant, antifibrotic, anti-inflammatory, antiproliferative, antiangiogenic, proapoptotic, or immunomodulatory properties, are independent of their influence on cholesterol levels.

To know more about hepatic cirrhosis treatment, visit @ *Hepatic Cirrhosis Treatment Drugs** *

*Key Hepatic Cirrhosis Therapies and Companies*

· Resmetirom: Madrigal Pharmaceuticals, Inc.
· Saroglitazar Magnesium: Zydus Therapeutics Inc.
· PHIN-214 Subcutaneous injection: PharmaIN
· RBX7455: Rebiotix Inc.
· Albutein 20% Injectable Solution: Grifols Therapeutics LLC
· Cabozantinib: Exelixis
· VIR-2218: Vir Biotechnology, Inc
· VIR-3434: Vir Biotechnology, Inc.
·  LPCN 1148: Lipocine Inc
· VE303: Vedanta Biosciences, Inc.
· Aldafermin: NGM Biopharmaceuticals, Inc
· BIV201 continuous infusion: BioVie Inc.
· OCE-205: Ocelot Bio, Inc
· Elafibranor: Genfit
· Seladelpar: CymaBay Therapeutics, Inc.
· Namodenoson: Can-Fite BioPharma
· BMS-986263: Bristol-Myers Squibb
· BI 685509: Boehringer Ingelheim
· EFX: Akero Therapeutics, Inc
· HTD1801: HighTide Biopharma Pty Ltd
· Bezafibrate: Intercept Pharmaceuticals
· K-877-ER: Kowa Research Institute, Inc.
· CNP-104: COUR Pharmaceutical Development Company, Inc.
· MGL-3196: Madrigal Pharmaceuticals, Inc.

Learn more about the FDA-approved drugs for hepatic cirrhosis @ *Drugs for* *Hepatic Cirrhosis Treatment** *

*Hepatic Cirrhosis Market Dynamics*

The hepatic cirrhosis market is expected to change in the coming years due to *increased disease awareness and healthcare spending* around the world, which will increase the size of the hepatic cirrhosis market and allow drug manufacturers to extend their hepatic cirrhosis market penetration. The United States is predicted to account for the greatest part of the hepatic cirrhosis market in the 7MM due to *favorable reimbursement scenarios*, i*ncreased R&D spending* in pharmaceutical companies and research institutes for *new medication development*, and the *presence of key players* in the domain. In addition, due to *increased awareness about new treatment options* and a *mature regulatory framework*, Europe is expected to be the second-largest market for liver cirrhosis therapy throughout the forecast period. 

Moreover, the Japanese market for liver cirrhosis treatment is expected to expand rapidly during the forecast period (2023–2032). The region’s hepatic cirrhosis market growth can be ascribed to an *increase in the prevalence* of liver illnesses and an *improvement in healthcare infrastructure*. Furthermore, the *hepatic cirrhosis pipeline* is highly robust; many possible therapies are being studied for hepatic cirrhosis treatment, and it is safe to assume that the therapeutic space will substantially impact the hepatic cirrhosis market throughout the forecast period.

However, certain factors may affect the growth of the hepatic cirrhosis market. The hepatic cirrhosis market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the hepatic cirrhosis market growth.

*Report Metrics* *Details*
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Hepatic Cirrhosis Companies Madrigal Pharmaceuticals, Inc., Zydus Therapeutics Inc., PharmaIN, Rebiotix Inc., Grifols Therapeutics LLC, Exelixis, Vir Biotechnology, Inc., Lipocine Inc, Vedanta Biosciences, Inc., NGM Biopharmaceuticals, Inc, BioVie Inc., Ocelot Bio, Inc, Genfit, CymaBay Therapeutics, Inc., Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Akero Therapeutics, Inc, HighTide Biopharma Pty Ltd, Intercept Pharmaceuticals, Kowa Research Institute, Inc., COUR Pharmaceutical Development Company, Inc., and others
Key Hepatic Cirrhosis Therapies Resmetirom, Saroglitazar Magnesium, PHIN-214 Subcutaneous injection, RBX7455, Albutein 20% Injectable Solution, Cabozantinib, VIR-2218, VIR-3434, LPCN 1148, VE303, Aldafermin, BIV201 continuous infusion, OCE-205, Elafibranor, Seladelpar, Namodenoson, BMS-986263, BI 685509, EFX, HTD1801, Bezafibrate, K-877-ER, CNP-104, MGL-3196, and others

*Scope of the **Hepatic Cirrhosis** Market Report*

· *Therapeutic Assessment: *Hepatic Cirrhosis current marketed and emerging therapies
· *Hepatic Cirrhosis* *Market Dynamics:* Attribute Analysis of Emerging Hepatic Cirrhosis Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Hepatic Cirrhosis Market Access and Reimbursement*

Discover more about hepatic cirrhosis drugs in development @ *Hepatic Cirrhosis Clinical Trials*

*Table of Contents*

1. Hepatic Cirrhosis Market Key Insights
2. Hepatic Cirrhosis Market Report Introduction
3. Hepatic Cirrhosis Market Overview at a Glance
4. Hepatic Cirrhosis Market Executive Summary
5. Disease Background and Overview
6. Hepatic Cirrhosis Treatment and Management
7. Hepatic Cirrhosis Epidemiology and Patient Population
8. Patient Journey
9. Hepatic Cirrhosis Marketed Drugs
10. Hepatic Cirrhosis Emerging Drugs
11. Seven Major Hepatic Cirrhosis Market Analysis
12. Hepatic Cirrhosis Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Related Reports*

*Hepatic Cirrhosis Pipeline*

*Hepatic Cirrhosis Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic cirrhosis companies, including *Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd.,* among others.

*Hepatic Cirrhosis Epidemiology Forecast*

*Hepatic Cirrhosis Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted hepatic cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*Nonalcoholic Steatohepatitis Market*

*Nonalcoholic Steatohepatitis** Market Insight, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including* Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, Cirius Therapeutics, *among others.

*Non-Alcoholic Fatty Liver Disease Market*

*Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including *AstraZeneca, Novartis, Pfizer, Roche, *among others.

*Non-Alcoholic Fatty Liver Disease Pipeline*

*Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced non-alcoholic fatty liver disease companies, including *AstraZeneca, Novartis, Pfizer, Roche, *among others.

*Nonalcoholic Steatohepatitis Epidemiology*

*Nonalcoholic Steatohepatitis Epidemiology Forecast **– 2032* report delivers an in-depth understanding of the disease, historical, and forecasted nonalcoholic steatohepatitis epidemiology in the 7MM.

*Other Trending Reports*

*Treatment Resistant Depression Market** |** Advanced Renal Cell Carcinoma Market** |** Hepatic Cirrhosis Market** |** Centronuclear Myopathy Market** |** Head And Neck Squamous Cell Carcinoma Market** |** Acquired Immunodeficiency Syndrome Market** |** Acute Intermittent Porphyria Market** |** Neurovascular Devices Market** |** Defibrillators Market** |** Ventricular Hypertrophy Market** |** Urolithiasis Market** |** Alopecia Areata Market** |** Autonomic Dysfunction Market** |** Acute Ischemic Stroke Ais Market** |** Adenoid Cystic Carcinoma Market** |** Aspergillosis Market** |** Biliary Atresia Market** |** Biliary Tumor Market** |** Chronic Inducible Urticaria Market* | *Chronic Insomnia Market** |** Critical Limb Ischemia Market** |** Endometriosis Pain Market** |** Generalized Anxiety Disorder Gad Market** |** Hallux Valgus Market** |** Hemophilia B Market** |** Immunologic Deficiency Syndrome Market** | **Neuromodulation Devices Market** |** Neurovascular Thrombectomy Devices Market** |** Osteosarcoma Market** |** Pemphigus Vulgaris Market** |** Progressive Familial Intrahepatic Cholestasis Market** |** Pruritus Market** |** Radiation Toxicity Market** |** Pulmonary Hypertension Associated With Interstitial Lung Disease Market** |** Cluster Headaches Market** |** Foot And Ankle Devices Market* | *Intravenous Immunoglobulin Market** |** Bile Duct Neoplasm Market** |** Blood Glucose Monitoring Systems Market** |** Rett Syndrome Market** |** Tissue Heart Valves Market** |** Cardiac Biomarkers Testing Devices Market** |** Subscription Healthcare** | **Hepatorenal Syndrome Market** |** Central Venous Catheters Market** |** Continuous Renal Replacement Therapy Machines Market** |** Nonalcoholic Steatohepatitis Market** |** Necrotizing Enterocolitis Market** |** Cardiac Amyloidosis Market** |** Artificial Iris Market** |** Aortic Aneurysm Stent Grafts Market** |** Polypoidal Choroidal Vasculopathy Market** |** Adrenal Crisis Market** |** Hearing Implants Market** |** Image Guided Surgery Devices Market** |** Angioedema Market** |** Bladder Cancer Market*

*Related Healthcare Services*

*Healthcare Consulting*

*Healthcare Competitive Intelligence Services*

*Healthcare Asset Prioritization Services*

*About DelveInsight*

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*

*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com